United Parcel Service (UPS) is investing $48 million in 27 new temperature-controlled facilities across the Americas, Europe, and Asia to capitalize on a booming healthcare logistics market. The move is driven by the growing demand for temperature-sensitive biologics and popular GLP-1 drugs like Wegovy. UPS's healthcare division generated its first $3 billion revenue quarter earlier this year, and the company aims to improve its cold-chain capabilities.
UPS facility investment
- ▪The new UPS facilities are located across the Americas, Europe, and Asia
- ▪The investment aims to improve speed and the end-to-end chain of custody for temperature-sensitive shipments
- ▪United Parcel Service (UPS) is investing $48 million in 27 new temperature-controlled facilities
Temperature-controlled logistics demand
- ▪The World Health Organization reports up to 50% of global vaccines are wasted annually, with a significant portion due to cold-chain storage issues
- ▪The demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033
- ▪The market for temperature-sensitive biologics is projected to reach a value of approximately $39.1 billion by 2033, according to Growth Market Reports
Healthcare revenue growth
- ▪UPS's global healthcare portfolio has gained market share every year since 2021
- ▪UPS CEO Carol Tomé identified healthcare as one of the company's top priorities and biggest areas of growth
- ▪In the first quarter of the year, UPS generated its first $3 billion healthcare revenue quarter
GLP-1 drug transportation
- ▪The rise of GLP-1 drugs has contributed to growing investments in temperature-controlled logistics
- ▪GLP-1 medicines like Novo Nordisk's Wegovy and Ozempic require strict refrigeration and temperature control during transit
- ▪A November KFF poll found that one in eight Americans are taking GLP-1 drugs
Story comments
Loading comments…